The evolving scenario of non-AIDS-defining cancers: Challenges and opportunities of care

Oncologist

Volumn 19, Issue 8, 2014, Pages 860-867

  Vaccher, Emanuela ^a   Serraino, Diego ^a   Carbone, Antonino ^a   De Paoli, Paolo ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

Chemotherapy; HIV; Immunodeficiency; Non AIDS defining cancers

Indexed keywords

BLEOMYCIN; BOCEPREVIR; CHLORMETHINE; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; MITOMYCIN; NAVELBINE; PREDNISONE; PROCARBAZINE; TELAPREVIR; VINBLASTINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANUS CANCER; ARTICLE; CANCER PROGNOSIS; CANCER RISK; CLINICAL TRIAL (TOPIC); COMORBIDITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HODGKIN DISEASE; HUMAN; IMMUNE RESPONSE; INCIDENCE; LIVER CELL CARCINOMA; LUNG CANCER; NEOPLASM; NON AIDS DEFINING CANCER; PRIORITY JOURNAL; SURVIVAL; CARCINOMA, HEPATOCELLULAR; COMPLICATION; HIV INFECTIONS; LIVER NEOPLASMS; LUNG NEOPLASMS; PATHOLOGY; PROCEDURES; RISK FACTOR;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CARCINOMA, HEPATOCELLULAR; HIV INFECTIONS; HODGKIN DISEASE; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; RISK FACTORS;

EID: 84905487213     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2014-0024     Document Type: Article

References (88)

1. Wada N, Jacobson LP, Cohen M et al. Cause specific life expectancies after 35 years of age for HIV-infected and human immunodeficiency syndrome negative individuals followed simultaneously in long term cohort studies, 1984-2008. Am J Epidemiol 2013; 177: 116-125.
2. Engels EA. Non-AIDS-defining malignancies in HIV-infected persons: Etiologic puzzles, epidemiologic perils, prevention opportunities. AIDS 2009; 23: 875-885.
3. Grulich AE, Jin F, Poynten IM et al. HIV, cancer, and aging. Sex Health 2011; 8: 521-525.
4. Greene M, Justice A, Lampiris H et al. Management of human immunodeficiency virus infection in advanced age. JAMA 2013; 309: 1397-1405.
5. Powles T, Robinson D, Stebbing J et al. Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infection. J Clin Oncol 2009; 27: 884-890.
6. Deeken JF, Tjen-A-Looi A, Rudek MA et al. The rising challenge of non-AIDS-defining cancers in HIV-infected patients. Clin Infect Dis 2012; 55: 1228-1235.
7. Dal Maso L, Polesel J, Serraino D et al. Pattern of cancer risk in persons with AIDS in Italy in the HAART era. Br J Cancer 2009; 100: 840-847.
8. A Review of Human Carcinogens: Biological Agents. Vol 100B: Lyon, France: International Agency for Research on Cancer, 2012.
9. Silverberg MJ, Chao C, Leyden WA et al. HIV infection and the risk of cancers with and without a known infectious cause. AIDS 2009; 23: 2337-2345.
10. Achenbach CJ, Cole SR, Kitahata MM et al. Mortality after cancer diagnosis in HIV-infected individuals treated with antiretroviral therapy. AIDS 2011; 25: 691-700.
11. Zucchetto A, Suligoi B, De Paoli A et al. Excess mortality for non-AIDS-defining cancers among people with AIDS. Clin Infect Dis 2010; 51: 1099-1101.
12. Serraino D, Piselli P, Busnach G et al. Risk of cancer following immunosuppression in organ transplant recipients and in HIV-positive individuals in southern Europe. Eur J Cancer 2007; 43: 2117-2123.
13. Grulich AE, van Leeuwen MT, Falster MO et al. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: A meta-analysis. Lancet 2007; 370: 59-67.
14. Shiels MS, Cole SR, Kirk GD et al. A metaanalysis of the incidence of non-AIDS cancers in HIVinfected individuals. J Acquir Immune Defic Syndr 2009; 52: 611-622.
15. Engels EA, Biggar RJ, Hall HI et al. Cancer risk in people infected with human immunodeficiency virus in the United States. Int J Cancer 2008; 123: 187-194.
16. Franceschi S, Lise M, Clifford GM et al. Changing patterns of cancer incidence in the earlyand late-HAART periods: The Swiss HIV Cohort Study. Br J Cancer 2010; 103: 416-422.
17. Polesel J, Franceschi S, Suligoi B et al. Cancer incidence in people with AIDS in Italy. Int J Cancer 2010; 127: 1437-1445.
18. Engels EA, Pfeiffer RM, Goedert JJ et al. Trends in cancer risk among people with AIDS in the United States 1980-2002. AIDS 2006; 20: 1645-1654.
19. Machalek DA, Poynten M, Jin F et al. Anal human papillomavirus infection and associated neoplastic lesions in men who have sex with men: A systematic review and meta analysis. Lancet Oncol 2012; 13: 487-500.
20. Hoots BE, Palefsky J, Pimenta J et al. Human papillomavirus type distribution in anal cancer and analintraepithelial lesions. Int J Cancer 2009; 124: 2375-2383.
21. Guiguet M, Boué F, Cadranel J et al. Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): A prospective cohort study. Lancet Oncol 2009; 10: 1152-1159.
22. Bertisch B, Franceschi S, Lise M et al. Risk factors for anal cancer in persons infected with HIV: A nested case-control study in the Swiss HIV Cohort Study. Am J Epidemiol 2013; 178: 877-884.
23. Engels EA, Madeleine MM. Invited commentary: Biological and clinical insights from epidemiologic research into HIV, HPV, and anal cancer. Am J Epidemiol 2013; 178: 885-887.
24. Oehler-Jänne C, Huguet F, Provencher S et al. HIV-specific differences in outcome of squamous cell carcinoma of the anal canal: A multicentric cohort study of HIV-positive patients receiving highly active antiretroviral therapy. J Clin Oncol 2008; 26: 2550-2557.
25. Fraunholz I, Rabeneck D, Gerstein J et al. Concurrent chemoradiotherapy with 5-fluorouracil and mitomycin C for anal carcinoma: Are there differences between HIV-positive and HIV-negative patients in the era of highly active antiretroviral therapy? Radiother Oncol 2011; 98: 99-104.
26. Abramowitz L, Mathieu N, Roudot-Thoraval F et al. Epidermoid anal cancer prognosis comparison among HIV1and HIV-patients. Aliment Pharmacol Ther 2009; 30: 414-421.
27. Munoz-Bongrand N, Poghosyan T, Zohar S et al. Anal carcinoma in HIV-infected patients in the era of antiretroviral therapy: A comparative study. Dis Colon Rectum 2011; 54: 729-735.
28. Chiao EY, Giordano TP, Richardson P et al. Human immunodeficiency virus-associated squamous cell cancer of the anus: Epidemiology and outcomes in the highly active antiretroviral therapy era. J Clin Oncol 2008; 26: 474-479.
29. Salama JK, Mell LK, Schomas DA et al. Concurrent chemotherapy and intensity-modulated radiation therapy for anal canal cancer patients: A multicenter experience. J Clin Oncol 2007; 25: 4581-4586.
30. Biggar RJ, Engels EA, Ly S et al. Survival after cancer diagnosis in persons with AIDS. J Acquir Immune Defic Syndr 2005; 39: 293-299.
31. Biggar RJ, Jaffe ES, Goedert JJ et al. Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS. Blood 2006; 108: 3786-3791.
32. Clifford GM, Rickenbach M, Lise M et al. Hodgkin lymphoma in the Swiss HIV Cohort Study. Blood 2009; 113: 5737-5742.
33. Küppers R. The biology of Hodgkin's lymphoma. Nat Rev Cancer 2009; 9: 15-27.
34. Grogg KL, Miller RF, Dogan A. HIV infection and lymphoma. J Clin Pathol 2007; 60: 1365-1372.
35. Carbone A, Cabras A, Gloghini A. HIVassociated Hodgkin's lymphoma. Antiapoptotic pathways and mechanisms for immune escape by tumor cells in the setting of improved immunity. Int J BiolMarkers 2007; 22: 161-163.
36. Novak RM, Richardson JT, Buchacz K et al. Immune reconstitution inflammatory syndrome: Incidence and implications for mortality. AIDS 2012; 26: 721-730.
37. Rajasuriar R, Khoury G, Kamarulzaman A et al. Persistent immune activation in chronic HIV infection: Do any interventions work? AIDS 2013; 27: 1199-1208.
38. Tirelli U, Errante D, Dolcetti R et al. Hodgkin's disease and human immunodeficiency virus infection: Clinicopathologic and virologic features of 114 patients from the Italian Cooperative Group on AIDS and Tumors. J Clin Oncol 1995; 13: 1758-1767.
39. Vaccher E, Spina M, Tirelli U. Clinical aspects and management of Hodgkin's disease and other tumours in HIV-infected individuals. Eur J Cancer 2001; 37: 1306-1315.
40. Carbone A, Spina M, Gloghini A et al. Classical Hodgkin's lymphoma arising in different host's conditions: Pathobiology parameters, therapeutic options, and outcome. Am J Hematol 2011; 86: 170-179.
41. Martis N, Mounier N. Hodgkin lymphoma in patients with HIV infection: A review. Curr Hematol Malig Rep 2012; 7: 228-234.
42. van Schalkwyk WA, Opie J, Novitzky N. The diagnostic utility of bone marrow biopsies performed for the investigation of fever and/or cytopenias in HIV-infected adults at Groote Schuur Hospital, Western Cape, South Africa. Int J Lab Hematol 2011; 33: 258-266.
43. Levine AM, Li P, Cheung T et al. Chemotherapy consisting of doxorubicin, bleomycin, vinblastine, and dacarbazine with granulocyte-colonystimulating factor in HIV-infected patients with newly diagnosed Hodgkin's disease: A prospective, multi-institutional AIDS clinical trials group study (ACTG 149). J Acquir Immune Defic Syndr 2000; 24: 444-450.
44. Xicoy B, Ribera JM, Miralles P et al. Results of treatment with doxorubicin, bleomycin, vinblastine and dacarbazine and highly active antiretroviral therapy in advanced stage, human immunodeficiency virus-related Hodgkin's lymphoma. Haematologica 2007; 92: 191-198.
45. Montoto S, Shaw K, Okosun J et al. HIV status does not influence outcome in patients with classical Hodgkin lymphoma treated with chemotherapy using doxorubicin, bleomycin, vinblastine, and dacarbazine in the highly active antiretroviral therapy era. J Clin Oncol 2012; 30: 4111-4116.
46. Spina M, Gabarre J, Rossi G et al. Stanford V regimen and concomitant HAART in 59 patients with Hodgkin disease and HIV infection. Blood 2002; 100: 1984-1988.
47. Spina M, Rossi G, Antinori A et al. VEBEP regimen and highly active antiretroviral therapy (HAART) in patients (PTS) with HD and HIV infection (HD-HIV). Ann Oncol 2008; 19(suppl 4): iv152. Abstract 227.
48. Hentrich M, Berger M, Wyen C et al. Stageadapted treatment of HIV-associated Hodgkin lymphoma: Results of a prospective multicenter study. J Clin Oncol 2012; 30: 4117-4123.
49. Corona G, Vaccher E, Spina M et al. Potential hazard drug-drug interaction between boosted protease inhibitors and vinblastine in HIV patients with Hodgkin's lymphoma. AIDS 2013; 27: 1033-1035.
50. Rudek MA, Flexner C, Ambinder RF. Use of antineoplastic agents in patients with cancer who have HIV/AIDS. Lancet Oncol 2011; 12: 905-912.
51. Michieli M, Mazzucato M, Tirelli U et al. Stem cell transplantation for lymphoma patients with HIV infection. Cell Transplant 2011; 20: 351-370.
52. Spitzer TR, Ambinder RF, Lee JY et al. Dose-reduced busulfan, cyclophosphamide, and autologous stem cell transplantation for human immunodeficiency virus-associated lymphoma: AIDS Malignancy Consortium study 020. Biol Blood Marrow Transplant 2008; 14: 59-66.
53. Hessamfar-Bonarek M, Morlat P, Salmon D et al. Causes of death in HIV-infected women: Persistent role of AIDS. The 'Mortalité 2000 & 2005' Surveys (ANRS EN19). Int J Epidemiol 2010; 39: 135-146.
54. Antiretroviral Therapy Cohort Collaboration. Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996-2006: Collaborative analysis of 13 HIV cohort studies. Clin Infect Dis 2010; 50: 1387-1396.
55. Revill PA, Littlejohn M, Ayres A et al. Identification of a novel hepatitis B virus precore/core deletion mutant in HIV/hepatitis B virus co-infected individuals. AIDS 2007; 21: 1701-1710.
56. Cabuang LM, Shaw T, Littlejohn M et al. In vitro replication phenotype of a novel (-1G) hepatitis B virus variant associated with HIV co-infection. J Med Virol 2012; 84: 1166-1176.
57. Vogel BE, Lee SJ, Hildebrand A et al. A novel integrin specificity exemplified by binding of the alpha v beta 5 integrin to the basic domain of the HIV Tat protein and vitronectin. J Cell Biol 1993; 121: 461-468.
58. Altavilla G, Caputo A, Trabanelli C et al. Prevalence of liver tumours in HIV-1 tat-transgenic mice treated with urethane. Eur J Cancer 2004; 40: 275-283.
59. Thio C. Hepatitis B and human immunodeficiency virus coinfection. Hepatology 2009; 49: S138-S145.
60. Tedeschi R, Pivetta E, Zanussi S et al. Quantification of hepatitis C virus (HCV) in liver specimens and sera from patients with human immunodeficiency virus coinfection by using the Versant HCV RNA 3.0 (branched DNA-based) DNA assay. J Clin Microbiol 2003; 41: 3046-3050.
61. Ioannou GN, Bryson CL, Weiss NS et al. The prevalence of cirrhosis and hepatocellular carcinoma in patients with human immunodeficiency virus infection. Hepatology 2013; 57: 249-257.
62. MacDonald D, Nelson M, Bower M et al. Hepatocellular carcinoma, human immunodeficiency virus and viral hepatitis in the HAART era. World J Gastroenterol 2008; 14: 1657-1663.
63. Balagopal A, Philp FH, Astemborski J et al. Human immunodeficiency virus-related microbial translocation and progression of hepatitis C. Gastroenterology 2008; 135: 226-233.
64. Puoti M, Bruno R, Soriano V et al. Hepatocellular carcinoma in HIV-infected patients: Epidemiological features, clinical presentation and outcome. AIDS 2004; 18: 2285-2293.
65. Bräu N, Fox RK, Xiao P et al. Presentation and outcome of hepatocellular carcinoma in HIVinfected patients: A U. S.-Canadian multicenter study. J Hepatol 2007; 47: 527-537.
66. Berretta M, Garlassi E, Cacopardo B et al. Hepatocellular carcinoma in HIV-infected patients: Check early, treat hard. The Oncologist2011; 16: 1258-1269.
67. Sulkowski MS. Current management of hepatitis C virus infection in patients with HIV coinfection. J Infect Dis 2013; 207(suppl 1): S26-S32.
68. Lim C, Goutte N, Gervais A et al. Standardized care management ensures similar survival rates in HIV-positive and HIV-negative patients with hepatocellular carcinoma. J Acquir Immune Defic Syndr 2012; 61: 581-587.
69. Clifford GM, Polesel J, Rickenbach M et al. Cancer risk in the Swiss HIV Cohort Study: Associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst 2005; 97: 425-432.
70. Tobacco Smoke and Involuntary Smoking. Vol 83. Lyon, France: International Agency for Research on Cancer, 2004.
71. TirelliU, SpinaM, Sandri S et al. Lung carcinoma in 36 patients with human immunodeficiency virus infection. Cancer 2000; 88: 563-569.
72. Chaturvedi AK, Pfeiffer RM, Chang L et al. Elevated risk of lung cancer among people with AIDS. AIDS 2007; 21: 207-213.
73. Wistuba II, Behrens C, Milchgrub S et al. Comparison of molecular changes in lung cancers in HIV-positive and HIV-indeterminate subjects. JAMA 1998; 279: 1554-1559.
74. el-Solh A, Kumar NM, Nair MP et al. An RGD containing peptide from HIV-1 Tat-(65-80) modulates protooncogene expression in human bronchoalveolar carcinoma cell line, A549. Immunol Invest 1997; 26: 351-370.
75. Sigel K, Wisnivesky J, Gordon K et al. HIV as an independent risk factor for incident lung cancer. AIDS 2012; 26: 1017-1025.
76. Pakkala S, Chen Z, Rimland D et al. Human immunodeficiency virus-associated lung cancer in the era of highly active antiretroviral therapy. Cancer 2012; 118: 164-172.
77. Brock MV, Hooker CM, Engels EA et al. Delayed diagnosis and elevated mortality in an urban population with HIV and lung cancer: Implications for patient care. J Acquir Immune Defic Syndr 2006; 43: 47-55.
78. Hakimian R, Fang H, Thomas L et al. Lung cancer in HIV-infected patients in the era of highly active antiretroviral therapy. J Thorac Oncol 2007; 2: 268-272.
79. LavoléA, Chouäi{dotless}d C, Baudrin L et al. Effect of highly active antiretroviral therapyon survival of HIV infected patients with non-small-cell lung cancer. Lung Cancer 2009; 65: 345-350.
80. D'Jaen GA, Pantanowitz L, Bower M et al. Human immunodeficiency virus-associated primary lung cancer in the era of highly active antiretroviral therapy: A multi-institutional collaboration. Clin Lung Cancer 2010; 11: 396-404.
81. Goldstraw P, Crowley J. The International Association for the Study of Lung Cancer international staging project on lung cancer. J Thorac Oncol 2006; 1: 281-286.
82. Makinson A, Tenon JC, Eymard-Duvernay S et al. Human immunodeficiency virus infection and non-small cell lung cancer: Survival and toxicity of antineoplastic chemotherapy in a cohort study. J Thorac Oncol 2011; 6: 1022-1029.
83. Bearz A, Vaccher E, Talamini R et al. Comment on 'Lung cancer in the Swiss HIV Cohort Study: Role of smoking, immunodeficiency and pulmonary infection'. Br J Cancer 2012; 106: 1899-1900.
84. Suneja G, Shiels MS, Melville SK et al. Disparities in the treatment and outcomes of lung cancer among HIV-infected individuals. AIDS 2013; 27: 459-468.
85. Rengan R, Mitra N, Liao K et al. Effect of HIV on survival in patients with non-small-cell lung cancer in the era of highly active antiretroviral therapy: A population-based study. Lancet Oncol 2012; 13: 1203-1209.
86. Serraino D, Zucchetto A, Suligoi B et al. Survival after AIDS diagnosis in Italy, 1999-2006: A population-based study. J Acquir Immune Defic Syndr 2009; 52: 99-105.
87. Lewden C, May T, Rosenthal E et al. Changes in causes of death among adults infected by HIV between 2000 and 2005: The "Mortalité 2000 and 2005" surveys (ANRS EN19 and Mortavic). J Acquir Immune Defic Syndr 2008; 48: 590-598.
88. Marin B, Thiébaut R, Bucher HC et al. NonAIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapy. AIDS 2009; 23: 1743-1753.